UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition

Journal of virology, 2017-09, Vol.91 (18)

2017

Volltextzugriff (PDF)

Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques

PLoS pathogens, 2019-02, Vol.15 (2), p.e1007552

2019

Volltextzugriff (PDF)

Resistance profile and mechanism of severe acute respiratory syndrome coronavirus-2 variants to LCB1 inhibitor targeting the spike receptor-binding motif

Frontiers in microbiology, 2022-10, Vol.13, p.1022006-1022006

2022

Volltextzugriff (PDF)

SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses

Signal transduction and targeted therapy, 2021-08, Vol.6 (1), p.294-294, Article 294

2021

Volltextzugriff (PDF)

In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to LP-40, Enfuvirtide-Based Lipopeptide Inhibitor

International journal of molecular sciences, 2022-06, Vol.23 (12), p.6638

2022

Volltextzugriff (PDF)

Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals

Science advances, 2020-11, Vol.6 (45)

2020

Volltextzugriff (PDF)

Broad Antiviral Activity and Crystal Structure of HIV-1 Fusion Inhibitor Sifuvirtide

The Journal of biological chemistry, 2012-02, Vol.287 (9), p.6788-6796

2012

Volltextzugriff (PDF)

Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy

Cellular & molecular immunology, 2021-03, Vol.18 (3), p.660-674

2021

Volltextzugriff (PDF)

Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor

PloS one, 2012-03, Vol.7 (3), p.e32599-e32599

2012

Volltextzugriff (PDF)

Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus

Emerging microbes & infections, 2021-01, Vol.10 (1), p.810-821

2021

Volltextzugriff (PDF)

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron

Emerging microbes & infections, 2022-12, Vol.11 (1), p.1819-1827

2022

Volltextzugriff (PDF)

Broad-spectrum anti-HIV activity and high drug resistance barrier of lipopeptide HIV fusion inhibitor LP-19

Frontiers in immunology, 2023-05, Vol.14, p.1199938-1199938

2023

Volltextzugriff (PDF)

Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy

Emerging microbes & infections, 2022-12, Vol.11 (1), p.30-49

2022

Volltextzugriff (PDF)

Design of a Bispecific HIV Entry Inhibitor Targeting the Cell Receptor CD4 and Viral Fusion Protein Gp41

Frontiers in cellular and infection microbiology, 2022-05, Vol.12, p.916487-916487

2022

Volltextzugriff (PDF)

Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action

Viruses, 2019-09, Vol.11 (9), p.811

2019

Volltextzugriff (PDF)

Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants

Emerging microbes & infections, 2021-01, Vol.10 (1), p.1227-1240

2021

Volltextzugriff (PDF)

Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity

Journal of virology, 2020-07, Vol.94 (14)

2020

Volltextzugriff (PDF)

Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors

Viruses, 2019-07, Vol.11 (7), p.609

2019

Volltextzugriff (PDF)

Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors

Viruses, 2020-03, Vol.12 (3), p.326

2020

Volltextzugriff (PDF)

Development of potent pan‐coronavirus fusion inhibitors with a new design strategy

MedComm (2020), 2024-08, Vol.5 (8), p.e666-n/a

2024

Volltextzugriff (PDF)

Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket

Frontiers in cellular and infection microbiology, 2018-02, Vol.8, p.51-51

2018

Volltextzugriff (PDF)

Epitope mapping of M36, a human antibody domain with potent and broad HIV-1 inhibitory activity

PloS one, 2013-06, Vol.8 (6), p.e66638

2013

Volltextzugriff (PDF)

DNA Duplexes with Hydrophobic Modifications Inhibit Fusion between HIV-1 and Cell Membranes

Antimicrobial Agents and Chemotherapy, 2013-10, Vol.57 (10), p.4963-4970

2013

Volltextzugriff (PDF)

Characterization of novel HIV fusion-inhibitory lipopeptides with the M-T hook structure

Microbes and infection, 2024-05, p.105366, Article 105366

2024

Volltextzugriff (PDF)

Detection of HEV antigen as a novel marker for the diagnosis of hepatitis E

Journal of medical virology, 2006-11, Vol.78 (11), p.1441-1448

2006

Volltextzugriff (PDF)

1 – 25 von 122

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(109)
Mit Volltextzugriff
(112)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(99)
Life Sciences & Biomedicine
(78)
Humans
(40)
Fusion Inhibitor
(35)
Hiv-1
(33)
Virology
(28)
Hiv Fusion Inhibitors - Pharmacology
(22)
Microbiology
(22)
Hiv-1 - Drug Effects
(20)
Hiv
(17)
Human Immunodeficiency Virus
(17)
Infectious Diseases
(17)
Hiv Fusion Inhibitors - Chemistry
(16)
Virus Internalization - Drug Effects
(16)
Human Immunodeficiency Virus 1
(15)
Immunology
(15)
Lipopeptide
(15)
Physical Sciences
(15)
Animals
(14)
Biochemistry & Molecular Biology
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition

Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppression in rhesus macaques

Resistance profile and mechanism of severe acute respiratory syndrome coronavirus-2 variants to LCB1 inhibitor targeting the spike receptor-binding motif

SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses

In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to LP-40, Enfuvirtide-Based Lipopeptide Inhibitor

Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals

Broad Antiviral Activity and Crystal Structure of HIV-1 Fusion Inhibitor Sifuvirtide

Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy

Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor

Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron

Broad-spectrum anti-HIV activity and high drug resistance barrier of lipopeptide HIV fusion inhibitor LP-19

Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy

Design of a Bispecific HIV Entry Inhibitor Targeting the Cell Receptor CD4 and Viral Fusion Protein Gp41

Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action

Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants

Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity

Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors

Structural and Functional Characterization of the Secondary Mutation N126K Selected by Various HIV-1 Fusion Inhibitors

Development of potent pan‐coronavirus fusion inhibitors with a new design strategy

Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket

Epitope mapping of M36, a human antibody domain with potent and broad HIV-1 inhibitory activity

DNA Duplexes with Hydrophobic Modifications Inhibit Fusion between HIV-1 and Cell Membranes

Characterization of novel HIV fusion-inhibitory lipopeptides with the M-T hook structure

Detection of HEV antigen as a novel marker for the diagnosis of hepatitis E

Suchergebnisse filtern